Literature DB >> 15794402

Jessner-Kanof lymphocytic infiltration of the skin associated with glatiramer acetate.

S Nolden1, C Casper, A Kuhn, H F Petereit.   

Abstract

Glatiramer acetate (GLAT) is a well tolerated and safe immunomodulatory drug for the treatment of relapsing-remitting multiple sclerosis. The most commonly recognized side effects are localized injection site reactions consisting of pain, pruritus, mild erythema and induration, which sometimes persist for several days. We describe the first case of a biopsy-proven lymphocytic infiltration (T-cell pseudolymphoma) with the clinical appearance of a figured erythema on the ventrolateral thighs in the first four weeks under GLAT treatment, resolving without any evidence of recurrence despite ongoing therapy. A T-cell pseudolymphoma is a very rare side effect of GLAT treatment. For clinical purposes it is important to state that re-exposition after GLAT-induced pseudolymphoma is possible without permanent sequelae.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15794402     DOI: 10.1191/1352458505ms1130cr

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  3 in total

1.  Ustekinumab-induced drug eruption resembling lymphocytic infiltration (of Jessner-Kanof) and lupus erythematosus tumidus.

Authors:  Claudio Guarneri; Maria Lentini; Giovanni Polimeni; Roberta Giuffrida; Serafinella P Cannavò
Journal:  Br J Clin Pharmacol       Date:  2015-12-29       Impact factor: 4.335

Review 2.  Cutaneous Adverse Effects of Neurologic Medications.

Authors:  Eman Bahrani; Chloe E Nunneley; Sylvia Hsu; Joseph S Kass
Journal:  CNS Drugs       Date:  2016-03       Impact factor: 6.497

3.  Possibly drug-induced palpable migratory arciform erythema.

Authors:  Fernando Luiz Teixeira Dantas; Neusa Yuriko Sakai Valente; Isis Suga Veronez; Priscila Kakizaki; Juliana Ribeiro Leitão; Rafael Cavanellas Fraga
Journal:  An Bras Dermatol       Date:  2015 May-Jun       Impact factor: 1.896

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.